Customizing the targeting of IGF-1 receptor

Future Oncol. 2009 Feb;5(1):43-50. doi: 10.2217/14796694.5.1.43.

Abstract

The type 1 IGF receptor (IGF-IR) is activated by two ligands, IGF-1 and IGF-2, and by insulin at supraphysiological concentrations. It plays a significant role in the growth of normal and abnormal cells, and antibodies against the IGF-IR are now in clinical trials. Targeting of the IGF-IR in cancer cells (by antibodies or other means) can be improved by the appropriate selection of responsive tumors. This review focuses on the optimization of IGF-IR targeting in human cancer.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Drug Delivery Systems / methods*
  • Humans
  • Insulin Receptor Substrate Proteins / metabolism
  • Neoplasms / drug therapy*
  • Receptor, IGF Type 1 / antagonists & inhibitors*
  • Receptor, IGF Type 1 / genetics
  • Receptor, IGF Type 1 / immunology

Substances

  • Antibodies
  • Antineoplastic Agents
  • IRS1 protein, human
  • Insulin Receptor Substrate Proteins
  • Receptor, IGF Type 1